{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to an insufficient number of participants with event.","groupId":"OG000","lowerLimit":"15.7","upperLimit":"NA","value":"22.4"},{"comment":"Upper limit of 95% CI was not estimable due to an insufficient number of participants with event.","groupId":"OG001","lowerLimit":"11.7","upperLimit":"NA","value":"17.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"Time to deterioration in PF = time from randomization to first observed ≥ 10-point decrease in EORTC QLQ-C30 linearly transformed PF scale score that is sustained for two consecutive assessments or followed by death while the participant is on treatment. EORTC QLQ-C30 consists of 30 questions that assess 5 aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). PF scale has 5 questions about participant's PF and daily activities (strenuous activities, long walks, short walks, bed/chair rest \\& needing help with eating, dressing, washing themselves, or using the toilet). PF are scored on a 4-point scale (1=Not at All to 4=Very Much). The obtained scores are linearly transformed to a score range of 0-100, where higher scores indicate a higher response level, functioning/support.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets), PO, BID along with cobimetinib, 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 960 mg (four, 240 mg tablets), PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab matching placebo as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21 and vemurafenib 960 mg (four, 240 mg tablets) PO, BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG000","title":"Arm A: Pbo + Cobi + Vem"},{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets) PO, BID along with cobimetinib 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 720 mg (three, 240 mg tablets) PO, BID and vemurafenib matching placebo, PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab 840 mg as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG001","title":"Arm B: Atezo + Cobi + Vem"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants, whether or not study treatment was received.","reportingStatus":"POSTED","timeFrame":"Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 33 months)","title":"Time to Deterioration in Physical Functioning (PF) Determined Using EORTC QLQ-C30 Scale Score","type":"SECONDARY","unitOfMeasure":"months"}